Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) in IMbrave150: a phase III clinical trial for unresectable hepatocellular carcinoma (HCC)
Abstract No : 4596
Indication : Hepatocellular Carcinoma
Intervention : atezolizumab + bevacizumab
Company : Roche
Technology : Monoclonal antibody
The ITT population included 336 pts randomized to atezo + bev and 165 pts randomized to sor. With a median follow-up of 8.6 mo (data cutoff, Aug 29, 2019), OS HR was 0.58 (95% CI: 0.42, 0.79;P= 0.0006) and PFS HR was 0.59 (95% CI: 0.47, 0.76; P , 0.0001) with atezo + bev vs sor. ORR was 27% vs 12% (P , 0.0001) per IRF RECIST 1.1 and 33% vs 13% (P , 0.0001) per IRF HCC mRECIST with atezo + bev vs sor, respectively. For responders (per IRF RECIST 1.1), median time to response was 2.8 mo (range, 1.2-11.3) with atezo + bev and 3.3 mo (range, 1.2-7.2) with sor. CR per IRF-assessed RECIST 1.1 was achieved by 18 pts in the atezo + bev arm and 0 pts in the sor arm. The baseline characteristics for atezo + bev CR pts are shown in the table. Additional characteristics will be shown
IMbrave150 demonstrated statistically significant and clinically meaningful improvement in both OS and PFS with atezo + bev vs sor in pts with unresectable HCC who have not received prior systemic therapy. Pts achieved CRs regardless of poor prognostic factors or etiology. Atezo + bev may be a practice-changing treatment for pts with unresectable HCC.
The HCC result for Atezolizumab + Bevacizumab may shift the treatment paradigsm for advanced HCC. IMbrave150 TRIAL demonstrated statistically significant and clinically meaningful improvement in both OS and PFS with atezolizumab + bevacizumab vs sorafenib in patients with unresectable HCC who had not received prior systemic therapy. In a disease with historically low CR rates, 6% patients achieved a CR with this combination vs 0% with sorafenib.